Core Viewpoint - AstraZeneca announced the approval of Ipupronit Sodium Injection (brand name Wainua) in China for the treatment of adult hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN), marking a significant milestone as it is the only gene-silencing agent approved for this condition in the country [1][6]. Group 1: Approval and Treatment Benefits - The approval is based on positive results from the NEURO-TTRansform Phase III clinical study, which demonstrated consistent and sustained clinical benefits in patients treated with Ipupronit Sodium compared to a placebo over a 66-week observation period [3][8]. - Key endpoints showed improvements in serum transthyretin (TTR) levels and neuropathy impairment scores, as well as quality of life assessments, indicating the drug's effectiveness [3][8]. Group 2: Disease Context and Treatment Mechanism - ATTRv-PN is a debilitating disease that can lead to peripheral nerve damage, with patients typically experiencing motor function impairment within five years of diagnosis and an average life expectancy of ten years without treatment [4][9]. - Ipupronit Sodium is administered monthly via an automatic injector, enhancing medication convenience and potentially improving patients' quality of life [1][6]. - The drug works by upstream inhibition of TTR production in the liver, making it a promising treatment for various types of transthyretin amyloidosis [4][9]. Group 3: Global Development and Ongoing Research - Ipupronit Sodium has also been approved in the United States and the European Union, with ongoing efforts to secure approvals in more countries [5][9]. - The drug is currently undergoing the CARDIO-TTRansform Phase III clinical study to evaluate its efficacy in treating adult transthyretin cardiac amyloidosis (ATTR-CM), which is the largest clinical study of its kind with over 1,400 participants [5][9].

Core Insights - AstraZeneca and Ionis Pharmaceuticals have jointly developed Ipupronit Sodium Injection, which has been approved by the National Medical Products Administration for the treatment of adult patients with hereditary transthyretin amyloidosis polyneuropathy (ATTRv-PN) [1] - Ipupronit Sodium is the first and currently the only gene-silencing agent approved for the treatment of ATTRv-PN in China [1] Group 1: Disease Overview - ATTR is caused by the accumulation of misfolded TTR protein produced by the liver, leading to organ damage and failure, with various complications affecting cardiovascular, neurological, and renal health [2] - ATTR has multiple phenotypes, including ATTR-CM (primarily affecting the heart) and ATTRv-PN (primarily affecting the peripheral nervous system), with ATTRv-PN being a debilitating disease that can lead to motor function impairment within five years of diagnosis [2] - The average age of onset for patients in China is 42 years, with a range from 17 to 68 years, and there is a significant delay of 3 to 4 years from symptom onset to diagnosis due to low awareness among the public and healthcare professionals [2] Group 2: Treatment Insights - Ipupronit Sodium is a gene-silencing agent administered once a month, which works by upstream inhibition of TTR protein production, showing potential for treating various types of transthyretin amyloidosis [3] - The approval of Ipupronit Sodium provides new hope for ATTRv-PN patients, as clinical evidence indicates it can halt the progression of neuropathy and significantly improve neurological function and quality of life [3]

Core Viewpoint - The approval of Wainua® (eplontersen) by AstraZeneca and Ionis for the treatment of ATTRv-PN in China represents a significant advancement in addressing a previously underserved medical need for patients suffering from this debilitating disease [1] Group 1: Product Approval - Wainua® is the first and currently the only gene-silencing agent approved in China for the treatment of ATTRv-PN [1] - The drug was officially approved on December 22, 2025, marking a milestone in the treatment options available for patients [1] Group 2: Disease Impact - ATTRv-PN is a debilitating disease that can lead to peripheral nerve damage, with patients typically experiencing motor function impairment within five years of diagnosis and a general mortality rate within ten years if untreated [1] - The disease has been included in China's second batch of rare disease catalog, highlighting its significance and the need for effective treatments [1] Group 3: Expert Commentary - Professor Zhang Shuyang, the chief researcher of EPIC-ATTR in China, emphasized the long-standing impact of ATTRv-PN on patients' neurological symptoms and quality of life, noting the limited treatment options available prior to the approval of Wainua® [1]